Mohit Manrao, SVP, Head of US Oncology AstraZeneca, shared on LinkedIn:
“This content is intended for US audiences only.
Today, AstraZeneca is proud to announce that the FDA has granted Priority Review for our investigational medicine as a 2nd-line and later treatment in advanced gastric cancers expressing Claudin 18.2 (CLDN18.2).
This decision is based on data from the Phase III CLARITY-Gastric01 trial presented just a few short weeks ago during a Presidential Symposia at ESMO – European Society for Medical Oncology (ESMO).
CLDN18.2 is a biomarker found in an estimated 60% of gastric/GEJ cancers and has emerged as an important therapeutic target. Most patients are diagnosed at an advanced stage, when prognosis is poor and treatment options are limited. In particular, these patients have no targeted treatment options after progressing on first-line therapy.
AstraZeneca’s push into biomarker-driven approaches is rapidly transforming the landscape for challenging tumor types and advanced disease.
We will keep following the science and pursuing biomarker-driven approaches that bring precision medicine to some of the most challenging cancers. Our ambition is to improve outcomes across every stage and today marks another encouraging step forward.
We look forward to working with the FDA through the Priority Review process.”
Read the press release here:
You may also be interested in:
Mohit Manrao: FDA Approves AstraZeneca’s VOLGA Trial Regimen for Muscle-Invasive Bladder Cancer
Florian Lordick: How Should We Choose First-Line Treatment When CLDN18.2 and PD-L1 Coexist?
FDA Grants Priority Review to Sonesitatug Vedotin for Advanced Gastric Cancer
